4//SEC Filing
CLOVER WOLF CAPITAL - LIMITED PARTNERSHIP 4
Accession 0001213900-21-030103
CIK 0001158780other
Filed
May 31, 8:00 PM ET
Accepted
Jun 1, 7:34 AM ET
Size
15.6 KB
Accession
0001213900-21-030103
Insider Transaction Report
Form 4
Transactions
- Sale
Common stock
2021-05-27$3.69/sh−24,110$88,966→ 3,236,925 total - Sale
Common Stock
2021-05-26$3.68/sh−122,663$451,400→ 3,354,825 total - Sale
Common Stock
2021-05-26$3.69/sh−22,015$81,235→ 3,332,810 total - Sale
Common stock
2021-05-28$3.72/sh−45,000$167,400→ 3,121,918 total - Sale
Common stock
2021-05-28$3.72/sh−70,007$260,426→ 3,166,918 total - Sale
Common stock
2021-05-27$3.69/sh−71,775$264,850→ 3,261,035 total
Footnotes (6)
- [F1]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from approximately $3.64 to $3.70 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F2]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from approximately $3.63 to $3.73 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from approximately $3.66 to $3.72 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from approximately $3.68 to $3.69 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from approximately $3.72 to $3.75 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F6]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from approximately $3.70 to $3.74 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Documents
Issuer
PLURISTEM THERAPEUTICS INC
CIK 0001158780
Entity typeother
Related Parties
1- filerCIK 0001810117
Filing Metadata
- Form type
- 4
- Filed
- May 31, 8:00 PM ET
- Accepted
- Jun 1, 7:34 AM ET
- Size
- 15.6 KB